Scoop has an Ethical Paywall
Scoop InfoPages
This InfoPage in unregistered, if this is your news page register Merck Sharp and Dohme NZ for InfoPages here.
Merck Sharp and Dohme NZ - Latest News [Page 1]
Eligible New Zealanders Can Now Access Lagevrio ® For The Treatment Of Mild To Moderate Covid-19
Thursday, 28 April 2022, 3:25 pm | Merck Sharp and Dohme NZ
Merck Sharp & Dohme (New Zealand) Limited (MSD) today announced that LAGEVRIO (molnupiravir) an oral antiviral treatment for adults with mild to moderate COVID-19, is available in New Zealand for those who meet the access criteria. 1,3 Merck Sharp ... More >>
Five Years Since KEYTRUDA® (pembrolizumab) Funded For Melanoma Patients But Many New Zealanders Still Waiting
Friday, 1 October 2021, 3:52 pm | Merck Sharp and Dohme NZ
1 October 2021, Merck Sharp & Dohme New Zealand Limited (MSD) says it is now five years since the funding of immunotherapy medicines for advanced melanoma (stage four) that had spread throughout the body and this is a milestone for patients. ... More >>
Thanks to New Zealand Clinical Trial Patients
Monday, 21 May 2018, 1:39 pm | Merck Sharp and Dohme NZ
Sunday May 20, marks International Clinical Trials Day and the chance to say thank you to New Zealand clinical trial patients around the country. More >>
KEYTRUDA® - now registered for bladder cancer
Thursday, 26 October 2017, 1:42 pm | Merck Sharp and Dohme NZ
26th October, 2017, KEYTRUDA® (pembrolizumab) is now registered by Medsafe for the treatment of patients with advanced urothelial carcinoma (a type of bladder cancer).[1] More >>
NZ 2nd in the world to register KEYTRUDA - chemo combination
Monday, 17 July 2017, 12:49 pm | Merck Sharp and Dohme NZ
New Zealand second in the world to register KEYTRUDA® - chemo combination July 14 , 2017, New Zealand follows the United States Food and Drug Administration (FDA) in being the second country worldwide to register KEYTRUDA® (pembrolizumab) in combination ... More >>
New medicine to fight Hepatitis C now registered
Thursday, 15 December 2016, 12:43 pm | Merck Sharp and Dohme NZ
15 December 2016, Merck Sharp & Dohme (New Zealand) Ltd (MSD) today announced ZEPATIER® (elbasvir/grazoprevir) has been registered by Medsafe for the treatment of chronic Hepatitis C – genotype 1, 3* and 4 infection in adults. Hepatitis C ... More >>
KEYTRUDA now registered to treat lung cancer
Monday, 29 August 2016, 10:26 am | Merck Sharp and Dohme NZ
August 29th 2016, MSD today announced that its anti-PD1 immunotherapy KEYTRUDA®(pembrolizumab) has been registered by Medsafe for New Zealand patients who have previously been treated for advanced non-small cell lung cancer (NSCLC) and whose tumours express ... More >>
Kiwis get rare opportunity to help protect against shingles
Friday, 9 March 2012, 2:29 pm | Merck Sharp and Dohme NZ
New Zealanders will soon have access to a limited supply of a vaccine to help protect against shingles, despite a global shortage of the vaccine. More >>
ISENTRESS Now Funded for NZ HIV Patients
Thursday, 1 October 2009, 4:57 pm | Merck Sharp and Dohme NZ
New Zealand HIV patients will now have another fully funded treatment option thanks to PHARMAC reimbursing ISENTRESSTM (raltegravir) from 1 October 2009. More >>
ISENTRESS Awarded Prix Galien USA Top Honor
Friday, 24 October 2008, 12:40 pm | Merck Sharp and Dohme NZ
Merck Sharp & Dohme's medicine for HIV/AIDS, recently received the Prix Galien USA 2008 Award for Best Pharmaceutical Agent. More >>
Many HIV-Positive Patients Still Fear Stigma
Thursday, 25 September 2008, 11:37 am | Merck Sharp and Dohme NZ
Results from the AIDS Treatment for Life International Survey (ATLIS), which polled nearly 3,000 HIV-positive patients from New Zealand and 17 other countries, show many people living with HIV and AIDS still live in fear of the societal stigma that ... More >>
Osteoporosis Medication Now Registered
Wednesday, 9 July 2008, 12:15 am | Merck Sharp and Dohme NZ
Merck Sharp & Dohme New Zealand (MSDNZ) has gained registration for its osteoporosis medication FOSAMAX PLUS™ 5600 IU. More >>
Maxalt MLT Now Fully Funded For Migraine Sufferers
Friday, 30 May 2008, 10:36 am | Merck Sharp and Dohme NZ
The estimated 400,000[ ] New Zealanders who suffer from migraine now have another choice of fully funded medication to battle this debilitating disorder. More >>
First DPP-4 Inhibitor for Type 2 Diabetes in NZ
Thursday, 28 February 2008, 3:26 pm | Merck Sharp and Dohme NZ
New Zealanders with Type 2 diabetes now have access to a new medicine which is significantly less likely to cause weight gain or dangerously low blood sugar; thanks to Merck Sharp & Dohme New Zealand's (MSDNZ) once-daily tablet, JANUVIA® (sitagliptin, MSD), ... More >>
Merck to Donate Three Million Doses of Gardasil
Wednesday, 17 October 2007, 10:43 am | Merck Sharp and Dohme NZ
Merck to Donate Three Million Doses of Gardasil®, its Cervical Cancer Vaccine, to Support Vaccination Programmes in Lowest Income Nations More >>
Final MEDAL Programme Results
Tuesday, 14 November 2006, 12:23 am | Merck Sharp and Dohme NZ
Large Outcomes Study Showed Merck & Co., Inc.'s ARCOXIA® (etoricoxib) Had Similar Rates of Cardiovascular Thrombotic Events Compared to Diclofenac, the Most Prescribed Traditional NSAID Worldwide In the Study, ARCOXIA Was Shown to Have Significantly ... More >>
Osteoporosis Medicine Decision Welcomed
Tuesday, 27 September 2005, 12:19 am | Merck Sharp and Dohme NZ
The decision to widen taxpayer-funded access to the osteoporosis medication Fosamax® will result in significant quality of life improvements for the estimated 30% of New Zealand women over the age of 50 who have osteoporosis. More >>
Shelford Committed To Influenza Vaccination
Monday, 9 May 2005, 11:28 am | Merck Sharp and Dohme NZ
Former All-Black captain, Buck Shelford says he’s committed to the “You’re never too fit to get hit” influenza vaccination campaign which starts tonight because of his personal experience with the potentially-deadly virus. More >>
Merck Statement on COX-2 Inhibitors
Friday, 29 April 2005, 2:45 pm | Merck Sharp and Dohme NZ
Alister Brown, managing director of Merck Sharp & Dohme New Zealand (MSD NZ), made the following comments in response to today’s announcement by the Ministry of Health that COX-2 inhibitors will remain available in New Zealand: More >>
Influenza Vaccine Deliveries On Track
Wednesday, 20 April 2005, 1:06 pm | Merck Sharp and Dohme NZ
Merck Sharp & Dohme NZ said that it expected to clear the backlog of reconfirmed VAXIGRIP® influenza vaccine orders from its distribution centre by late afternoon today. More >>
